Openbookopenbook
Equity
Moderna Inc.(0A45)
USD --+0.00%
Reward59Moderate
Risk57Medium-High
📊50%Data
Thin -145% profit margin · Revenue down 30% YoY
0A45
+0.0 · +0.00%
USD · LSE
Moderna Inc. |
Profitless Growth
Market Cap:—
ℹ️
Reward Rating
59
Moderate
Top 50% (model universe)
50% data coverage
ℹ️
Risk Rating
57
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0A45 to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Moderna Inc.?

, a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

0A45 · Verdict

Solid reward · elevated risk

0A45 stands out on balance sheet and growth, but watch the cash flow signal.

Based on 75% data coverage

0A45 · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet88/100

    Current ratio 2.73

  • Growth70/100

    Above average

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Volatility35/100

    Below average

  • Profitability44/100

    -29% return on equity

Model-based scoring. For information only — not financial advice.

What is Moderna Inc.?

, a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E Ratio0.0491
Dividend YieldN/A
52 Week High58.71
52 Week Low22.25
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees4,700
IndustryN/A
ExchangeLSE
Beta1.336
CurrencyUSD
Websitewww.modernatx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.